Glaukos Corporation released an investor presentation outlining its focus on interventional glaucoma and interventional keratoconus. The company highlighted its commercial portfolio and pipeline, including iDose TR for ocular hypertension and open-angle glaucoma, noting FDA approval for re-administration in January 2026 and clinical data showing 81% of subjects were free of IOP-lowering topical medications at 12 months and 70% were well-controlled on the same or fewer medications at three years. Glaukos also discussed iDose TRIO, which is in a Phase 3b study, and iDose TREX, which is advancing through a Phase 2b/3 program. In keratoconus, Glaukos presented Epioxa, described as an FDA-approved epithelium-on corneal cross-linking treatment, and stated it is expected to be commercially available in the first quarter of 2026. The presentation also referenced a third-generation iLink program that is currently in Phase 2 clinical trials. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.